Oral Proteins and Peptides Market Top Companies Study- AstraZeneca, Biocon Chiasma, Novo Nordisk A/S, Allergan.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Oral Proteins and Peptides Market"-, By Type of Target Disease Indication (Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, and Type II Diabetes), Type of Molecule (Protein and Peptide), Type of Biological Target (GC-C, Insulin Receptor, Oxalate and others), Type of Mechanism of Action (Receptor Stimulation, Substrate Degradation and Others), and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."

The Oral Proteins and Peptides Market is estimated to reach over USD 28.17 billion by 2031, exhibiting a CAGR of 20.3% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2868

Proteins and peptides, essential biological components, possess significant therapeutic potential for the treatment of various diseases. Over the past three decades, particularly in the last ten years, the development of therapeutic proteins has progressed substantially, leading to a notable increase in the number of protein-based drugs available in the market. However, the oral bioavailability of these molecules remains a challenge due to their fragile tertiary structure and complex spatial conformation, which are prone to degradation in the harsh environment of the gastrointestinal tract. To enhance the oral availability of peptides, advancements in their formulation are expected to improve absorption. Notable examples of therapeutic peptides, such as Octreotide utilizing Peptelligence technology and oral semaglutide based on Eligen technology, have already progressed to clinical stages.

Recent innovations in peptide formulation technologies have substantially improved the bioavailability of oral peptide therapies. Approaches such as nanoparticle encapsulation, structural modifications of peptides, and the incorporation of permeation enhancers have proven effective in safeguarding peptides from degradation in the gastrointestinal tract, thereby making oral administration a more viable option. Oral peptides offer a non-invasive alternative to injectable treatments, enhancing patient compliance and adherence to long-term care regimens, which is especially important for managing chronic conditions.

Moreover, regulatory support for novel therapies, including Fast Track Designation and Breakthrough Therapy Designation from agencies like the FDA, has expedited the approval process for oral peptides, allowing for quicker market access. Collaborations between pharmaceutical companies, biotechnology firms, and academic institutions are crucial in accelerating the discovery and development of innovative oral protein and peptide therapies, promoting knowledge exchange and resource optimization. Furthermore, increased investment in research and development by pharmaceutical and biotechnology companies is expected to drive the identification of new peptides with therapeutic applications, further fueling market growth and innovation.

List of Prominent Players in the Oral Proteins and Peptides Market:
• AstraZeneca
• Biocon Chiasma
• Novo Nordisk A/S
• Allergan
• Oramed Pharmaceuticals
• Proxima Concepts
• Synergy Pharmaceuticals
• Tarsa Therapeutics
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novo Nordisk A/S
• Abbvie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• Chiesi Farmaceutici S.P.A.
• Acadia Pharmaceuticals Inc.
• Aurinia Pharmaceuticals Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Swk Holdings
• R-Pharm Jsc
• Entera Bio Ltd.
• Proxima Concepts
• Astrazeneca Plc
• Regor Therapeutics Group
• Terns Pharmaceuticals, Inc.
• Structure Therapeutics
• Viking Therapeutics
• Protagonist Therapeutics Inc.
• Rani Therapeutics
• Carmot Therapeutics, Inc.
• Zealand Pharma
• Sciwind Biosciences Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics:
Drivers:
Advancements such as nanoparticle carriers, enteric coatings, and enzyme inhibitors have significantly enhanced the stability and bioavailability of proteins and peptides, making oral delivery increasingly feasible. The growing prevalence of chronic conditions, including diabetes, cancer, and hormonal disorders, is driving the demand for effective and patient-friendly treatment options. Regulatory bodies, such as the FDA, have been approving innovative oral protein and peptide therapies, thereby fostering confidence in the development of these treatments and encouraging further investment. Oral formulations, including those in development for insulin and other peptide-based therapies, present a non-invasive alternative to traditional injections, offering the potential to improve patient compliance and overall quality of life. These innovations position oral proteins and peptides as a promising solution for managing chronic diseases in the future, addressing the rising demand for more accessible, patient-friendly therapies. Furthermore, the aging global population, which is more susceptible to chronic diseases, is contributing to an increased demand for advanced, easy-to-administer treatments, further propelling market expansion.

Challenges:
The development of stable and effective oral formulations of proteins and peptides remains a complex challenge. The necessity for advanced formulation techniques, such as encapsulation or modification strategies, leads to higher development costs and extended timelines. A primary obstacle in the oral delivery of proteins and peptides is their low bioavailability due to degradation by gastrointestinal enzymes and the acidic environment in the stomach.

Regional Trends:
North America is expected to maintain the largest market share during the forecast period, driven by a strong focus on research and development and significant investments from biotechnology and pharmaceutical companies in innovative peptide therapies. Favorable regulatory frameworks, such as Fast Track and Breakthrough Therapy Designations, expedite the approval process for new oral peptide therapies. In contrast, the Asia-Pacific region is projected to experience the highest growth rate, owing to increased healthcare expenditures, a growing patient population, and greater awareness of peptide-based therapies. Efforts to streamline regulatory processes in emerging markets are accelerating the approval of innovative therapies. Countries such as China and India are seeing substantial investments in biotechnology, which is driving research activities and the development of oral peptide therapies in these regions.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2868

Recent Developments:
• In June 2023, Pfizer Inc. declared its intention to proceed with the clinical development of a single oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate for the possible treatment of people with Type 2 diabetes mellitus (T2DM) and obesity. Subject to the outcomes of the ongoing Phase 2 trial, the company will proceed with the clinical development of lotiglipron (PF-07081532) and continue to advance the clinical program for danuglipron (PF-06882961). The business is working on a once-daily modified release version of danuglipron and anticipates having preparations for the late-stage program finalized by the end of 2023.
• In August 2023, Entera Bio, presented abstracts at the annual conference of the American Society for Bone and Mineral Research (ASBMR) on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the treatment of postmenopausal women at high risk of fracture.

Segmentation of Oral Proteins and Peptides Market.
Global Oral Proteins and Peptides Market- Type of Target Disease Indication
• Acromegaly
• Celiac Disease
• Chronic Idiopathic Constipation
• Enteric Hyperoxaluria
• Inflammatory Bowel Disease
• Type II Diabetes
Global Oral Proteins and Peptides Market - Type of Molecule
• Protein
• Peptide
Global Oral Proteins and Peptides Market - Type of Biological Target
• GC-C
• Insulin Receptor
• Oxalate
• Others
Global Oral Proteins and Peptides Market - Type of Mechanism of Action
• Receptor Stimulation
• Substrate Degradation
• Others
Global Oral Proteins and Peptides Market - By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/oral-proteins-and-peptides-market/2868

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.